Sifting through countless of stocks in the Life Sciences Tools & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in West Pharmaceutical Services, Inc. or Stevanato Group S.p.A. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how West Pharmaceutical Services, Inc. and Stevanato Group S.p.A. compare based on key financial metrics to determine which better meets your investment needs.

About West Pharmaceutical Services, Inc. and Stevanato Group S.p.A.

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Latest Life Sciences Tools & Services and West Pharmaceutical Services, Inc., Stevanato Group S.p.A. Stock News

As of September 2, 2026, West Pharmaceutical Services, Inc. had a $24.1 billion market capitalization, compared to the Life Sciences Tools & Services median of $3.7 million. West Pharmaceutical Services, Inc.’s stock is up 23.4% in 2026, down 1.9% in the previous five trading days and up 40.57% in the past year.

Currently, West Pharmaceutical Services, Inc.’s price-earnings ratio is 43.9. West Pharmaceutical Services, Inc.’s trailing 12-month revenue is $3.3 billion with a 17.0% net profit margin. Year-over-year quarterly sales growth most recently was 13.8%. Analysts expect adjusted earnings to reach $8.959 per share for the current fiscal year. West Pharmaceutical Services, Inc. currently has a 0.3% dividend yield.

As of September 2, 2026, Stevanato Group S.p.A. had a $5.7 billion market cap, putting it in the 69th percentile of all stocks. Stevanato Group S.p.A.’s stock is up 2.1% in 2026, down 7.8% in the previous five trading days and down 8.48% in the past year.

Currently, Stevanato Group S.p.A.’s price-earnings ratio is 37.0. Stevanato Group S.p.A.’s trailing 12-month revenue is $1.4 billion with a 11.0% net profit margin. Year-over-year quarterly sales growth most recently was 4.9%. Analysts expect adjusted earnings to reach $0.704 per share for the current fiscal year. Stevanato Group S.p.A. currently has a 0.3% dividend yield.

How We Compare West Pharmaceutical Services, Inc. and Stevanato Group S.p.A. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at West Pharmaceutical Services, Inc. and Stevanato Group S.p.A.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

West Pharmaceutical Services, Inc. and Stevanato Group S.p.A. Stock Value Grades

Company	Ticker	Value
West Pharmaceutical Services, Inc.	WST	F
Stevanato Group S.p.A.	STVN	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

West Pharmaceutical Services, Inc. has a Value Score of 12, which is Ultra Expensive. Stevanato Group S.p.A. has a Value Score of 25, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither West Pharmaceutical Services, Inc. or Stevanato Group S.p.A. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if West Pharmaceutical Services, Inc. or Stevanato Group S.p.A. is the better investment when it comes to value.

West Pharmaceutical Services, Inc. and Stevanato Group S.p.A.’s Momentum Grades

Company	Ticker	Momentum
West Pharmaceutical Services, Inc.	WST	B
Stevanato Group S.p.A.	STVN	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

West Pharmaceutical Services, Inc. has a Momentum Score of 69, which is Strong. Stevanato Group S.p.A. has a Momentum Score of 42, which is Average.

The Momentum Grade Winner: West Pharmaceutical Services, Inc.

As you can clearly see from the Momentum Grade breakdown above, West Pharmaceutical Services, Inc. is considered to have stronger momentum compared to Stevanato Group S.p.A.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, West Pharmaceutical Services, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

West Pharmaceutical Services, Inc. and Stevanato Group S.p.A.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
West Pharmaceutical Services, Inc.	WST	B
Stevanato Group S.p.A.	STVN	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

West Pharmaceutical Services, Inc. has a Earnings Estimate Score of 75, which is Positive. Stevanato Group S.p.A. has a Earnings Estimate Score of 53, which is Neutral.

The Earnings Estimate Revisions Grade Winner: West Pharmaceutical Services, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, West Pharmaceutical Services, Inc. has a better Earnings Estimate Revisions Grade than Stevanato Group S.p.A.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, West Pharmaceutical Services, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other West Pharmaceutical Services, Inc. and Stevanato Group S.p.A. Grades

In addition to Momentum, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether West Pharmaceutical Services, Inc. and Stevanato Group S.p.A. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, West Pharmaceutical Services, Inc. or Stevanato Group S.p.A. Stock?

Overall, West Pharmaceutical Services, Inc. stock has a Value Score of 12, Momentum Score of 69 and Estimate Revisions Score of 75.

Stevanato Group S.p.A. stock has a Value Score of 25, Momentum Score of 42 and Estimate Revisions Score of 53.

Comparing West Pharmaceutical Services, Inc. and Stevanato Group S.p.A.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.